[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 479
6. Dziurzynski K, Delashaw JB, Gultekin SH, Yedinak CG, Fleseriu M: Diabetes insipidus, panhypopituitarism, and severe mental status deterioration in a patient with chordoid glioma: case report and literature review. Endocr Pract; 2009 Apr;15(3):240-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At that time, laboratory workup and magnetic resonance imaging (MRI) revealed no brain lesions or other hormonal irregularities.
  • Slow, progressive symptomatology in the following 3 years included mental status changes, nonhealing skin lesions, recurrent infections, temperature dysregulation, and midsection weight gain.
  • Biopsy samples from the third ventricular lesion revealed a circumscribed glial tumor.
  • Chordoid glioma is a rare tumor, and the 50 previously reported cases have been located in the suprasellar region.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diabetes Insipidus / diagnosis. Glioma / diagnosis. Hypopituitarism / diagnosis. Mental Disorders / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


7. Arita H, Izumoto S, Kinoshita M, Okita Y, Hashimoto N, Fujita T, Ichimaru N, Takahara S, Yoshimine T: Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports. Neurol Med Chir (Tokyo); 2010;50(12):1079-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
  • PTLD sometimes involves the central nervous system (CNS), but the clinical characteristics are not well recognized.
  • Two of the 631 patients (0.32%) developed CNS PTLD.
  • A 40-year-old Japanese woman suffered onset of CNS PTLD 5 years after renal transplantation.
  • She underwent second biopsy and the diagnosis was recurrent CNS PTLD.
  • A 61-year-old woman suffered onset of CNS PTLD 19 years after renal transplantation.
  • After tumor removal, whole brain irradiation was performed.
  • The first case of polymorphic CNS PTLD was successfully treated by modulation of immunosuppressants without radiation therapy even at recurrence.
  • PTLD should be included in the differential diagnosis of brain tumors in recipients of solid organ transplantation, and histological subtype should be carefully identified to establish the correct treatment strategy.
  • [MeSH-major] Central Nervous System Diseases / pathology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adult. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Steroids / administration & dosage. Steroids / adverse effects. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206182.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Steroids; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


8. Amthauer H, Wurm R, Kuczer D, Ruf J, Michel R, Eisenacher J, Stockhammer F, Denecke T, Felix R, Plotkin M: Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor. Clin Nucl Med; 2006 Apr;31(4):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor.
  • PURPOSE: The aim of the study was to investigate the impact of MR/SPECT image fusion on the interpretation of I-123 iodo-methyl-tyrosine (IMT) SPECT examinations in patients with pretreated brain tumors.
  • MATERIAL AND METHODS: In this retrospective study, 45 consecutive patients with suspected recurrent/residual gliomas (n = 41) or cerebral metastases (n = 4) were included.
  • SPECT studies were performed using a triple-head gamma-camera system 10 minutes after injection of 300 to 370 MBq (8.1-10 mCi) I-123 IMT.
  • Tumor localization and extent were evaluated and correlated with histopathology or clinical follow up, including MR imaging.
  • RESULTS: In 10 of 45 (22%) patients, image fusion had a significant impact on the interpretation of scans: 5 suspected SPECT findings were correctly classified as physiological or therapy-related; in another 5 patients, image fusion added relevant clinical information on tumor extent (infiltration of the contralateral hemisphere n = 3, infiltration of the brain stem n = 2).
  • [MeSH-major] Brain Neoplasms / pathology. Iodine Radioisotopes. Magnetic Resonance Imaging. Methyltyrosines. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550008.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 14684-02-7 / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


9. Zubenko GS, Hughes HB 3rd: Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. Mol Psychiatry; 2009 Apr;14(4):390-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous genetic studies have revealed significant evidence of linkage of the cAMP-responsive element-binding protein 1 (CREB1) gene region (2q33-35) to mood disorders among women from families with recurrent, early-onset MDD (RE-MDD), a severe and familial subtype of MDD.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Psychiatry. 1999 Nov 1;46(9):1219-33 [10560027.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Jul 5;147B(5):579-85 [18213625.001]
  • [Cites] Mol Psychiatry. 2000 Mar;5(2):131-6 [10822339.001]
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2275-80 [11001930.001]
  • [Cites] Nat Med. 2001 May;7(5):541-7 [11329053.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Apr;77(1):19-27 [11358671.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):193-203 [11457657.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] J Appl Physiol (1985). 2001 Dec;91(6):2785-801 [11717247.001]
  • [Cites] Brain Res Brain Res Rev. 2001 Dec;38(1-2):79-128 [11750928.001]
  • [Cites] Am J Med Genet. 2001 Dec 8;105(8):690-9 [11803516.001]
  • [Cites] Am J Med Genet. 2002 Mar 8;114(2):214-21 [11857584.001]
  • [Cites] Biol Reprod. 2002 Mar;66(3):659-66 [11870072.001]
  • [Cites] Neuron. 2002 Mar 14;33(6):845-8 [11906692.001]
  • [Cites] Neuron. 2002 Mar 28;34(1):13-25 [11931738.001]
  • [Cites] Am J Med Genet. 2002 May 8;114(4):413-22 [11992563.001]
  • [Cites] Mol Psychiatry. 2002;7(5):460-7 [12082563.001]
  • [Cites] Am J Med Genet. 2002 Dec 8;114(8):980-7 [12457397.001]
  • [Cites] Mol Psychiatry. 2003 Jun;8(6):611-8 [12851637.001]
  • [Cites] Science. 2003 Jul 18;301(5631):386-9 [12869766.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):39-43 [12898573.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2003 Nov 15;123B(1):1-18 [14582139.001]
  • [Cites] J Neurochem. 2004 Jun;89(6):1313-7 [15189333.001]
  • [Cites] Endocrinology. 1993 Feb;132(2):770-80 [8381074.001]
  • [Cites] J Neurosci. 1993 Mar;13(3):1280-91 [7680068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10947-51 [7971989.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3534-45 [7628390.001]
  • [Cites] J Neurochem. 1996 Apr;66(4):1770-3 [8627337.001]
  • [Cites] J Neurochem. 1998 Nov;71(5):1865-74 [9798910.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):279-307 [10368772.001]
  • [Cites] Genomics. 1999 Sep 1;60(2):121-8 [10486203.001]
  • [Cites] Trends Neurosci. 2005 Aug;28(8):436-45 [15982754.001]
  • [Cites] Dement Geriatr Cogn Disord. 2006;22(1):95-8 [16710089.001]
  • [Cites] Brain Res. 2006 Dec 18;1126(1):2-26 [16978590.001]
  • [Cites] Neurochem Res. 2007 Apr-May;32(4-5):577-95 [16944320.001]
  • [Cites] Arch Gen Psychiatry. 2007 Jun;64(6):689-97 [17548750.001]
  • [Cites] Biol Psychiatry. 2007 Sep 1;62(5):536-40 [17300755.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35607-13 [10585438.001]
  • (PMID = 18317463.001).
  • [ISSN] 1476-5578
  • [Journal-full-title] Molecular psychiatry
  • [ISO-abbreviation] Mol. Psychiatry
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH047346; United States / NIMH NIH HHS / MH / MH060866-04; United States / NIMH NIH HHS / MH / MH43261; United States / NIMH NIH HHS / MH / R01 MH043261; United States / NIMH NIH HHS / MH / MH047346-13; United States / NIMH NIH HHS / MH / R01 MH047346-13; United States / NIMH NIH HHS / MH / MH47346; United States / NIMH NIH HHS / MH / MH60866; United States / NIMH NIH HHS / MH / R01 MH060866-04; United States / NIMH NIH HHS / MH / R01 MH043261-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Gonadal Steroid Hormones; E0399OZS9N / Cyclic AMP; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase; EC 3.2.1.23 / beta-Galactosidase
  • [Other-IDs] NLM/ NIHMS178794; NLM/ PMC2830064
  •  go-up   go-down


10. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • METHODS: Twenty-two patients aged 24 to 60 years with recurrent AO were treated.
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • CONCLUSIONS: Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent 1p19q codeleted alkylator-refractory AO.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


11. Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K: Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med; 2006 Mar;47(3):393-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
  • The aim of the present study was to evaluate whether extended analyses of O-(2-18F-fluoroethyl)-L-tyrosine (FET) uptake kinetics provide results superior to those of standard tumor-to-background ratios in predicting tumor grade in patients with pretreated gliomas.
  • METHODS: Dynamic 18F-FET PET studies (0-40 min after injection of 180 MBq of 18F-FET) were performed on 45 glioma patients with suspected tumor recurrence after multimodal treatment.
  • RESULTS: The parameters taking into account the individual time course of 18F-FET uptake were able to differentiate low-grade from high-grade recurrent astrocytomas with high diagnostic accuracy, reaching the best differentiation with a sensitivity and specificity of 92% and an area under the ROC curve (AUC) of 0.94.
  • Time-activity curves (5-40 min after injection) slightly and steadily increased in tumor-free patients and in low-grade tumors, whereas high-grade tumors showed an early peak around 10-15 min after injection followed by a decrease.
  • CONCLUSION: This study has shown differences in the dynamics of 18F-FET uptake between recurrent low- and high-grade gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Glioma / metabolism. Glioma / radionuclide imaging. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / radionuclide imaging. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Algorithms. Brain / metabolism. Brain / radionuclide imaging. Computer Simulation. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Kinetics. Male. Metabolic Clearance Rate. Middle Aged. Models, Biological. Positron-Emission Tomography / methods. ROC Curve. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Nucl Med. 2006 May;47(5):806
  • (PMID = 16513607.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine
  •  go-up   go-down


12. Reddy KS: Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet; 2008 Jul 15;184(2):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A majority of the 10 recurrent gliomas had progressed, and 70% had a 1p/19q deletion.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Glioma / genetics. In Situ Hybridization, Fluorescence / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617055.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Rahmah NN, Sakai K, Nakayama J, Hongo K: Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev; 2010 Apr;33(2):167-73; discussion 173
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical study was performed in 19 samples (initial, n = 11; recurrent, n = 8) from 11 patients.
  • [MeSH-minor] Adult. Aged. Child. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Neurosurgical Procedures. Prognosis. Tissue Distribution. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):471-8 [12904990.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1422-34 [16224208.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):105-12 [15696970.001]
  • [Cites] Neurosurgery. 1995 May;36(5):887-96; discussion 896-7 [7791978.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1442-8 [9030352.001]
  • [Cites] Pediatr Dev Pathol. 2005 May-Jun;8(3):362-8 [16010499.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):675-83 [17828469.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):857-62; discussion 862-3 [11564246.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2710-5 [12767082.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:165-70 [15662803.001]
  • [Cites] Neurosurgery. 2002 Sep;51(3):753-60; discussion 760 [12188955.001]
  • [Cites] J Med Invest. 2005 Aug;52(3-4):151-8 [16167532.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):209-11 [12062160.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):39-45 [14756439.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):101-8 [16324834.001]
  • [Cites] J Orthop Res. 2007 May;25(5):696-702 [17262820.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1779-84 [12738734.001]
  • [Cites] Brain. 1998 Dec;121 ( Pt 12):2327-34 [9874483.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):217-23 [17949787.001]
  • [Cites] J Neurosurg. 2003 Apr;98(4):812-22 [12691407.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4746-53 [15269148.001]
  • [Cites] Clin Neuropathol. 2001 Jan-Feb;20(1):26-30 [11220692.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):926-30 [15539385.001]
  • [Cites] Eur Urol. 2007 May;51(5):1259-66 [16806661.001]
  • [Cites] Lung Cancer. 2007 Dec;58(3):376-83 [17714826.001]
  • [Cites] Ann Diagn Pathol. 2002 Aug;6(4):222-8 [12170453.001]
  • (PMID = 19862564.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RECK protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


1
Advertisement
4. Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC: Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. Neurosurg Focus; 2010 Jan;28(1):E12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasion of adjacent tissue (dura mater, bone, venous sinus, brain) was found in 32 cases.
  • Additionally, alanine and the glycine/alanine ratio distinguished between primary and recurrent meningiomas (all p < 0.05).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine / metabolism. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Glutamic Acid / metabolism. Glycine / metabolism. Humans. Male. Middle Aged. Prognosis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043716.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3KX376GY7L / Glutamic Acid; MU72812GK0 / Creatine; N91BDP6H0X / Choline; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


15. Li F, Zhu S, Liu Y, Chen G, Chi L, Qu F: Hyperdense intracranial epidermoid cysts: a study of 15 cases. Acta Neurochir (Wien); 2007 Jan;149(1):31-9; discussion 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gross-total excision of the tumor was achieved in ten patients (66.7%).
  • CONCLUSIONS: Recurrent leakage of the irritating cyst contents and subsequent chemical inflammatory response may be responsible for the high-density on CT scans and the cystic nature.
  • [MeSH-major] Brain Diseases / diagnosis. Epidermal Cyst / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151831.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


16. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE: A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol; 2009 Mar;92(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
  • Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial.
  • Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Everolimus. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. PTEN Phosphohydrolase / biosynthesis. Pilot Projects. Proto-Oncogene Proteins c-akt. Quinazolines / administration & dosage. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / biosynthesis. Sirolimus / administration & dosage. Sirolimus / adverse effects. Sirolimus / analogs & derivatives


17. Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U: Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS; 2010 Aug;118(8):585-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
  • Several recent studies have demonstrated a beneficial effect of anti-angiogenic treatment with the vascular endothelial growth factor-neutralizing antibody bevacizumab in recurrent high-grade glioma.
  • Tumor tissue was obtained from a previous phase II study, treating recurrent primary glioblastoma multiforme (GBM) patients with the EGFR inhibitor cetuximab in combination with bevacizumab and irinotecan.
  • Of the 37 patients with available tumor tissue, 29 were evaluable for response.
  • We concurrently performed immunohistochemical stainings on tumor tissue from 21 GBM patients treated with bevacizumab and irinotecan.
  • [MeSH-major] Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neovascularization, Pathologic / diagnosis. Receptor, Epidermal Growth Factor / analysis
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cell Hypoxia. Cetuximab. Drug Therapy, Combination. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666740.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer; 2010 Nov 15;116(22):5297-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
  • BACKGROUND: The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG).
  • METHODS: Patients received bevacizumab 15 mg/kg every 3 weeks and were evaluated every 6 weeks until tumor progression.
  • Tissue correlates were used to quantify tumor content of vascular endothelial growth factor A (VEGFA) and vascular endothelial growth factor receptor-2 (VEGFR2).
  • For patients with GBM, the 6-month progression-free survival rate was 25%, the median time to tumor progression was 10.8 weeks, and the median overall survival was 25.6 weeks.
  • The ratio of tumor VEGFA/VEGFR2 was increased in patients aged >55 years; an increased VEGFA/VEGFR2 ratio was correlated nonsignificantly with decreased survival (P = .052).
  • CONCLUSIONS: An every-3-week schedule of bevacizumab had antitumor activity and was relatively nontoxic for patients with recurrent HGG.
  • The predictive value of VEGFA/VEGFR2 in tumor will require validation in a larger patient cohort.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-2 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20665891.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


19. Shim KW, Joo SY, Kim SH, Choi JU, Kim DS: Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray. J Neurosurg Pediatr; 2008 Mar;1(3):196-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Medulloblastoma is the most common malignant neuroepithelial tumor found in children.
  • In addition, the authors tried to determine the prognostic utility of these results in this tumor category.
  • RESULTS: There was no statistically significant correlation between the prognosis and the degree of cell differentiation, but a positive correlation was noted between the PI and the AI in a tumor mass.
  • The number of cases with a PI > 10% was significantly greater in the group of tumors in patients with recurrent medulloblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Apoptosis / physiology. Cell Differentiation / physiology. Cell Proliferation. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Forecasting. Humans. Immunohistochemistry. Male. Microarray Analysis. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Receptor, ErbB-3 / analysis. Receptor, trkC / analysis. Retrospective Studies. Treatment Outcome


20. Da Fonseca CO, Silva JT, Lins IR, Simão M, Arnobio A, Futuro D, Quirico-Santos T: Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs; 2009 Dec;27(6):557-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
  • BACKGROUND: The aim of this study was to establish a correlation of tumor topography and peritumoral brain edema with the therapeutic response to intranasal administration of perillyl alcohol (POH) in a cohort of patients with recurrent malignant gliomas.
  • METHODS: The retrospective study reviewed clinical and neuroradiological data from patients with recurrent malignant gliomas who received intranasal daily administration of POH 440 mg.
  • The following parameters were assessed: demographic characteristics, initial symptoms, overall survival, tumor topography and tumor size, presence of midline shift and extent of peritumoral edema.
  • Accordingly to tumor topography lobar localization was present in all (5/5) AO; eight (8/10) and 41 GBM patients whereas in the basal ganglia two AA and 11 GBM patients.
  • It was also observed a relation between the tumor size and area of peritumoral brain edema (PTBE).
  • Patients with good therapeutic response showed reduction of tumor size and PTBE area, but poor prognosis was associated with lack of response to treatment and persistence of high PTBE.
  • Patients with tumor in the basal ganglia survived significantly longer than those with lobar gliomas (log rank test, p = 0.0003).
  • (1) patients with recurrent gliomas with localization in the basal ganglia survive significantly longer than those with tumors at lobar localization;.
  • These findings support the theory that interaction between glioma cells at distinct brain microenvironment can influence the oncobiological behavior of glioma cells and ultimately to the prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Edema / pathology. Brain Neoplasms / drug therapy. Glioma / drug therapy. Glioma / pathology. Monoterpenes / therapeutic use. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Administration, Intranasal. Adult. Aged. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Neurol. 2005 Jul;4(7):413-22 [15963444.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Mar;28(3):462-9 [17353313.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):65-73 [8699228.001]
  • [Cites] J BUON. 2007 Apr-Jun;12(2):239-43 [17600879.001]
  • [Cites] Vojnosanit Pregl. 2003 Mar-Apr;60(2):147-54 [12852156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1359-62 [11121634.001]
  • [Cites] Surg Neurol. 2006;65 Suppl 1:S1:2-1:8; discussion S1:8-1:9 [16427438.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):760-9 [17460461.001]
  • [Cites] Surg Neurol. 2006 Dec;66(6):611-5 [17145324.001]
  • [Cites] Am J Dermatopathol. 2008 Aug;30(4):381-4 [18645311.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):267-76 [18726148.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] J Neurol Sci. 2007 Sep 15;260(1-2):49-56 [17475281.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):211-7 [15980971.001]
  • [Cites] Neurol India. 2002 Mar;50(1):37-40 [11960149.001]
  • [Cites] Glia. 2008 Jun;56(8):917-24 [18383343.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7 [18295834.001]
  • [Cites] Bull Mem Acad R Med Belg. 2007;162(5-6):331-8 [18405003.001]
  • [Cites] Bull Cancer. 2008 Jan;95(1):51-6 [18230570.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Acta Neurochir Suppl. 2003;85:47-53 [12570137.001]
  • [Cites] J Neurol Sci. 2003 Dec 15;216(1):1-10 [14607296.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):1-9 [17204931.001]
  • [Cites] Onkologie. 2004 Jun;27(3):261-6 [15249715.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • (PMID = 19139816.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Monoterpenes; 319R5C7293 / perillyl alcohol
  •  go-up   go-down


21. Aksoy S, Abali H, Kiliçkap S, Güler N: Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma. J Neurooncol; 2005 Feb;71(3):333-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Chondrosarcoma, Mesenchymal / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm / drug effects. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome


22. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH: Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol; 2007 Aug;84(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature.
  • Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors which occur almost exclusively in infants and young children.
  • There have been only 17 cases of AT/RT in adults reported in the medical literature and the rarity of this tumor makes the diagnosis in adults difficult.
  • We describe a case of an AT/RT of the spinal cord in an adult.
  • The patient underwent three additional surgical procedures for recurrent disease throughout the neuraxis secondary to leptomeningeal spread of the tumor.
  • To our knowledge, this is the first case of a spinal atypical teratoid/rhabdoid tumor in an adult fully documented with molecular, immunohistochemical, cytogenetic and autopsy findings.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. Neoplasm Recurrence, Local / pathology. Rhabdoid Tumor / pathology. Spinal Cord Neoplasms / pathology. Teratoma / pathology. Transcription Factors / genetics
  • [MeSH-minor] Adult. Cervical Vertebrae. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Monosomy / diagnosis. Monosomy / genetics. SMARCB1 Protein

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):665-70 [15769941.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 17377740.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 34
  •  go-up   go-down


23. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • It is used as a predictor of therapy efficacy and to localize remaining and recurrent tissue as well as local and distant extension.
  • CONCLUSION: Three-phase 99mTc-tectrofosmin scan is useful in detection of malignant lesions of the musculoskeletal system due to its high sensitivity and positive predictive value.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


24. Korones DN, Smith A, Foreman N, Bouffet E: Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer; 2006 Jul;47(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
  • BACKGROUND: Children and young adults with recurrent or treatment-induced malignant gliomas have limited responses to temozolomide or oral VP-16 when either is administered as a single agent.
  • We postulated that a combination of these two drugs for patients with recurrent or treatment-induced malignant gliomas might result in better and more prolonged responses.
  • PROCEDURE: Eleven patients with recurrent or treatment-induced malignant gliomas were treated with varying combinations of temozolomide (150-210 mg/m2/d for 5 days) and oral VP-16 (50 mg/m2/d for 4-12 days).
  • Diagnoses included recurrent brain stem glioma (2), recurrent anaplastic astrocytoma (2), and glioblastoma (7) (3 treatment-induced, 2 malignant transformations of lower grade tumors, 1 recurrence, and 1 second tumor arising 10 months after diagnosis of medulloblastoma).
  • CONCLUSIONS: These data suggest there is activity of temozolomide in combination with oral VP-16 for children and young adults with recurrent malignant gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Child. Child, Preschool. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16047359.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


25. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol; 2007 Feb;81(3):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
  • BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).
  • OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM.
  • PATIENTS AND METHODS: Eligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. North America. Survival Analysis. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS J. 2005 Mar 22;7(1):E14-9 [16146335.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2675-81 [11555579.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Drug Discov Today. 2005 Jan 15;10(2):107-14 [15718159.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-5 [16085015.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2481-7 [12894531.001]
  • [Cites] Arch Neurol. 1981 Nov;38(11):696-9 [6975612.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):193-201 [14558594.001]
  • [Cites] Arch Surg. 1975 Aug;110(8):888-91 [1171673.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Med. 1983 Aug;75(2):289-94 [6881181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] J Neurooncol. 1994;19(3):245-50 [7807175.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6 [11550138.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] Immunopharmacology. 1996 Mar;31(2-3):213-21 [8861747.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d100-16 [12456339.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1675-80 [8496685.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • (PMID = 17031561.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


26. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol; 2010 Aug;12(8):855-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
  • The objective of this phase II single-arm study was to evaluate the efficacy and safety of pazopanib, a multi-targeted tyrosine kinase inhibitor, against vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor-alpha and -beta, and c-Kit, in recurrent glioblastoma.
  • Brain magnetic resonance imaging and clinical reassessment were made every 8 weeks.
  • Grade 3/4 toxicities included leukopenia (n = 1), lymphopenia (n = 2), thrombocytopenia (n = 1), ALT elevation (n = 3), AST elevation (n = 1), CNS hemorrhage (n = 1), fatigue (n = 1), and thrombotic/embolic events (n = 3); 8 patients required dose reduction.
  • Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients (6 at the 8-week point and 3 only within the first month of treatment) had decreased contrast enhancement, vasogenic edema, and mass effect but <50% reduction in tumor.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52 [2845420.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] PLoS One. 2009;4(4):e5123 [19352490.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • (PMID = 20200024.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00459381
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062421-12; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01RR03186; United States / NCI NIH HHS / CA / CA62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  • [Other-IDs] NLM/ PMC2940686
  •  go-up   go-down


27. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology; 2009 Jul;252(1):182-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
  • PURPOSE: To determine if apparent diffusion coefficient (ADC) histogram analysis can stratify progression-free survival in patients with recurrent glioblastoma multiforme (GBM) prior to bevacizumab treatment.
  • Bevacizumab-treated and control patients (41 per cohort) diagnosed with recurrent GBM were analyzed by using whole enhancing tumor ADC histograms with a two normal distribution mixture fitting curve on baseline (pretreatment) magnetic resonance (MR) images to generate ADC classifiers, including the overall mean ADC as well as the mean ADC from the lower curve (ADC(L)).
  • For bevacizumab-treated patients, pretreatment ADC more accurately stratified 6-month progression-free survival than did change in enhancing tumor volume at first follow-up (73% vs 58% accuracy, P = .034).
  • CONCLUSION: Pretreatment ADC histogram analysis can stratify progression-free survival in bevacizumab-treated patients with recurrent GBM.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / drug therapy. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Algorithms. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Image Interpretation, Computer-Assisted / methods. Male. Middle Aged. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19561256.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


28. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M: Tumor recurrence and malignant progression of gangliogliomas. Cancer; 2008 Dec 15;113(12):3355-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and malignant progression of gangliogliomas.
  • BACKGROUND: Most gangliogliomas (GGs) are benign tumors, but tumor recurrence and malignant progression are observed in some patients.
  • METHODS: The authors analyzed their experience with 4 recurrent/progressive GGs (World Health Organization [WHO] grade I), 21 tumors with atypical features (WHO grade II), and 5 tumors with anaplastic histologic features (WHO grade III).
  • Secondary glioblastomas were diagnosed in 5 of 11 patients (45%) who underwent surgery for tumor recurrence.
  • Neuropathologic examination revealed the presence of a gemistocytic cell component (PFS, P = .025), a lack of protein droplets (OS, P = .04; PFS, P = .05), and focal tumor cell-associated CD34 immunolabeling (OS, P = .03) as significant predictors of an adverse clinical course.
  • CONCLUSIONS: The current data supported a 3-tiered GG histopathologic grading system that included an intermediate diagnostic category (atypical GG, WHO grade II).
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Epilepsy / epidemiology. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988291.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs; 2005 Aug;23(4):357-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
  • The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug.
  • Treatment was continued until unacceptable toxicity, tumor progression, or patient withdrawal.
  • CONCLUSIONS: CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent GBM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Anticonvulsants / administration & dosage. Anticonvulsants / therapeutic use. Disease-Free Survival. Drug Interactions. Female. Humans. Hypercholesterolemia / chemically induced. Infusions, Intravenous. Lymphopenia / chemically induced. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Mol Pharmacol. 1998 Nov;54(5):815-24 [9804616.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6141-5 [12414639.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):359-67 [11438483.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):169-74 [7671460.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):268-77 [12356357.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1071-7 [12234610.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1527-32 [11245461.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5406-12 [11103942.001]
  • [Cites] Drug Resist Updat. 2001 Dec;4(6):378-91 [12030785.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):331-9 [12704666.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • (PMID = 16012795.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455-08; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCI NIH HHS / CA / U01 CA62407-08; United States / NCI NIH HHS / CA / U01CA62421-08
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


30. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO: High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol; 2005 Dec;40(12):743-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
  • MATERIALS AND METHODS: In a prospective study, 41 patients withoncologic diseases underwent [F]-fluoro-2-deoxy-D-glucose PET-CT for tumor staging and WB-MRI on a 32-channel-scanner with the use of PAT.
  • Coronal T1w and STIR sequences at 5 body levels, axial HASTE imaging of the lung, and contrast-enhanced T1w sequences of the liver, brain, and abdomen were performed.
  • RESULTS: Three primary and 4 recurrent tumors were detected; one recurrent tumor was missed with WB-MRI.
  • CONCLUSION: WB-MRI and PET-CT are reliable imaging modalities for tumor staging.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304476.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Threatt S, Friedman HS: Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res; 2009 Feb 1;15(3):1064-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
  • PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy.
  • On gross total resection of the tumor, up to eight Gliadel wafers were implanted.
  • Treatment-related toxicity with this drug combination included grade 3 hydrocephalus (9.6%), grade 3 cerebrospinal fluid (CSF) leak (19.2%), and grade 3 CSF/brain infection (13.4%).
  • Although systemically administered O6-BG can be coadministered with Gliadel wafers safely, it may increase the risk of hydrocephalus, CSF leak, and CSF/brain infection.
  • Future trials are required to verify that inhibition of tumor AGT levels by O6-BG results in increased efficacy of Gliadel wafers without added toxicity.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):876-80 [2997415.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):573-7 [2926498.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1299-302 [8512814.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] J Neurooncol. 1994;21(2):135-40 [7861189.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Biomaterials. 1995 Sep;16(14):1069-72 [8519927.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):837-47 [9815757.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • (PMID = 19188181.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R37 CA 011898-38; United States / NINDS NIH HHS / NS / 5P50 NS20023-25; United States / NCI NIH HHS / CA / CA108786-040002; United States / NCI NIH HHS / CA / 5P50 CA108786-4; United States / NINDS NIH HHS / NS / P50 NS020023-250018; United States / NCRR NIH HHS / RR / TL1 RR024126; United States / NCI NIH HHS / CA / R37 CA011898; United States / NINDS NIH HHS / NS / NS020023-250018; United States / NCI NIH HHS / CA / P50 CA108786-040002
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Decanoic Acids; 0 / Polyesters; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS98019; NLM/ PMC2710963
  •  go-up   go-down


32. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ: Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol; 2009 Dec;11(6):861-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with suspected or recurrent GBM were examined with [(18)F]Galacto-RGD PET.
  • Standardized uptake values (SUVs) of tumor hotspots, galea, and blood pool were derived by region-of-interest analysis.
  • Tumor samples taken from areas with intense tracer accumulation in the [(18)F]Galacto-RGD PET images and were analyzed histologically and immunohistochemically for alpha(v)beta(3) integrin expression.
  • While normal brain tissue did not show significant tracer accumulation (mean SUV, 0.09 +/- 0.04), GBMs demonstrated significant but heterogeneous tracer uptake, with a maximum in the highly proliferating and infiltrating areas of tumors (mean SUV, 1.6 +/- 0.5).
  • Immunohistochemical staining was prominent in tumor microvessels as well as glial tumor cells.
  • In areas of highly proliferating glial tumor cells, tracer uptake (SUVs) in the [(18)F]Galacto-RGD PET images correlated with immunohistochemical alpha(v)beta(3) integrin expression of corresponding tumor samples.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Galactose / analogs & derivatives. Glioma / radionuclide imaging. Integrin alphaVbeta3 / metabolism. Peptides, Cyclic. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Female. Fluorine Radioisotopes. Humans. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiopharmaceuticals. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2001 Nov;14(11):1126-32 [11706074.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17703-11 [2447074.001]
  • [Cites] Nuklearmedizin. 2002;41(4):184-90 [12224402.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3033-40 [10447947.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3282-92 [16829652.001]
  • [Cites] Curr Pharm Des. 2006;12(22):2723-47 [16918408.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Sep;6(5):407-28 [17017851.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1651-7 [17470857.001]
  • [Cites] Neurology. 2007 May 22;68(21):1762-3 [17515537.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6 [18006761.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):22-9 [18077538.001]
  • [Cites] J Magn Reson Imaging. 2008 Feb;27(2):368-75 [18183585.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):378-86 [18394009.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Aug;17(8):1225-35 [18616418.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):643-7 [11299820.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):595-608 [11516703.001]
  • [Cites] Curr Drug Targets. 2003 Feb;4(2):123-31 [12558065.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Neuroimage. 2004 Aug;22(4):1523-33 [15275909.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • (PMID = 19401596.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC2802406
  •  go-up   go-down


33. Belda-Iniesta C, Carpeño Jde C, Saenz EC, Gutiérrez M, Perona R, Barón MG: Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther; 2006 Aug;5(8):912-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is responsible for most of the deaths associated with primary brain tumors.
  • Cetuximab is a monoclonal antibody targeted against the extra cellular domain of the EGFR with activity against different tumor types, either alone or in combination with chemotherapy and/or radiation therapy.
  • Here we describe three patients with recurrent, heavily pretreated, EGFR expressing GBM who responded to treatment with single agent cetuximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Female. Humans. Magnetic Resonance Imaging. Male. Receptor, Epidermal Growth Factor / metabolism


34. Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J: Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol; 2007 Mar;31(3):351-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sarcomatous component developed in recurrent/progressive tumors in 6 cases but was a focal finding at first tumor resection in 1 and included fibrosarcoma (n=5), leiomyosarcoma (n=1), or pleomorphic myogenic sarcoma (n=1).
  • Rhabdoid change was a focal finding in the sarcomatous component of 1 tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasms, Second Primary / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Brain / surgery. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychiatric Status Rating Scales / statistics & numerical data. Severity of Illness Index. Sex Factors. Time Factors


36. Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE: Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res; 2008 Feb 15;14(4):1124-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
  • PURPOSE: VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors.
  • Central imaging review confirmed that three patients had stable disease for a median of 45 weeks (range, 37-61+) after therapy.
  • CONCLUSIONS: The recommended dose of VNP40101M for phase II studies in children with brain tumors is 45 mg/m(2)/d in moderately pretreated and 30 mg/m(2)/d in heavily pretreated patients when administered for 5 consecutive days every 6 weeks.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Hydrazines / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Child, Preschool. Humans. Infant. Maximum Tolerated Dose

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281546.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00188; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  •  go-up   go-down


37. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC: Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol; 2007 Feb;33(1):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current study was undertaken to examine the mRNA expression of survivin isoforms and their correlation with clinical staging and outcome in 20 medulloblastoma (MB) tumours, three MB cell lines and normal brain tissues (a foetal and an adult cerebellum) by densitometry scanning of 32p-dCTP incorporated reverse transcription polymerase chain reaction (RT-PCR) products and quantitative real-time PCR.
  • Our results showed that the normal adult brain only expressed low levels of survivin-deltaEx3 mRNA, while the foetal brain expressed all three isoforms, with wild-type survivin as the dominant transcript.
  • Although overexpressions of survivin were not associated with the presence of metastatic MB or tumour histological subtypes, elevated expressions of survivin-deltaEx3 were significantly associated with progressive/recurrent tumours (P-value = 0.024).
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Isomerism. Male. Neoplasm Staging. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239009.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


38. Hafez RF: Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result. World J Surg Oncol; 2007;5:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Low-grade gliomas are uncommon primary brain tumors, located more often in the posterior fossa, optic pathway, and brain stem and less commonly in the cerebral hemispheres.
  • CASE PRESENTATIONS: Two patients with diagnosed recurrent cystic pilocytic astrocytoma critically located within the brain (thalamic and brain stem) were treated with gamma knife surgery.
  • Progressive reduction on the magnetic resonance imaging (MRI) studies of the solid part of the tumor and almost disappearance of the cystic component was achieved within the follow-up period of 36 months in the first case with the (thalamic located lesion) and 22 months in the second case with the (brain stem located lesion).
  • CONCLUSION: Gamma knife surgery represents an alternate tool in the treatment of recurrent and/or small postoperative residual pilocytic astrocytoma especially if they are critically located.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Thalamic Diseases / pathology. Thalamic Diseases / surgery. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):43-51 [12007940.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):677-80 [12507119.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1132-9; discussion [16331161.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):50-4 [9757318.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:19-24 [15662774.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • (PMID = 17394660.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1852107
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


39. Mimeault M, Batra SK: Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev; 2009 Apr;8(2):94-112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.
  • Recent advancements in tissue-resident adult stem/progenitor cell research have revealed that enhanced telomere attrition, oxidative stress, ultraviolet radiation exposure and oncogenic events leading to severe DNA damages and genomic instability may occur in these immature and regenerative cells during chronological aging.
  • Particularly, the alterations in key signaling components controlling their self-renewal capacity and an up-regulation of tumor suppressor gene products such as p16(INK4A), p19(ARF), ataxia-telangiectasia mutated (ATM) kinase, p53 and/or the forkhead box O (FOXOs) family of transcription factors may result in their dysfunctions, growth arrest and senescence or apoptotic death during the aging process.
  • These molecular events may culminate in a progressive decline in the regenerative functions and the number of tissue-resident adult stem/progenitor cells, and age-related disease development.
  • Conversely, the telomerase re-activation and accumulation of numerous genetic and/or epigenetic alterations in adult stem/progenitor cells with advancing age may result in their immortalization and malignant transformation into highly leukemic or tumorigenic cancer-initiating cells and cancer initiation.
  • Therefore, the cell-replacement and gene therapies and molecular targeting of aged and dysfunctional adult stem/progenitor cells including their malignant counterpart, cancer-initiating cells, hold great promise for treating and even curing diverse devastating human diseases.
  • These diseases include premature aging diseases, hematopoietic, cardiovascular, musculoskeletal, pulmonary, ocular, urogenital, neurodegenerative and skin disorders and aggressive and recurrent cancers.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Retin Eye Res. 2000 Jan;19(1):113-29 [10614683.001]
  • [Cites] Exp Gerontol. 2000 Jul;35(4):489-502 [10959037.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):114-7 [10973262.001]
  • [Cites] Haematologica. 2000 Nov;85(11):1222-4 [11064478.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):248-54 [11089982.001]
  • [Cites] Postgrad Med J. 2001 May;77(907):312-7 [11320273.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3399-408 [11423990.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):49-56 [11426628.001]
  • [Cites] Mech Ageing Dev. 2001 Sep 30;122(14):1537-53 [11511395.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jan;41(1):29-40 [11796230.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14877-83 [11836256.001]
  • [Cites] J Pathol. 2002 Jul;197(4):492-509 [12115865.001]
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):191-9 [12169393.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] J Neurochem. 2002 Dec;83(6):1509-24 [12472904.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):643-8 [12540856.001]
  • [Cites] Curr Mol Med. 2003 Mar;3(2):107-25 [12630558.001]
  • [Cites] J Appl Physiol (1985). 2003 Nov;95(5):2089-98 [14555672.001]
  • [Cites] Blood Rev. 2003 Dec;17(4):217-25 [14556776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):828-39 [14871958.001]
  • [Cites] J Neurosci. 2004 Feb 18;24(7):1726-33 [14973255.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Exp Eye Res. 2004 Mar;78(3):433-46 [15106923.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3317-26 [15161685.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4302-8 [15205345.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] J Dermatol Sci. 2004 Aug;35(2):113-23 [15265523.001]
  • [Cites] J Med Genet. 2004 Aug;41(8):609-14 [15286156.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7290-6 [15378089.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8354-65 [15385618.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):997-1002 [15496926.001]
  • [Cites] Exp Gerontol. 2004 Oct;39(10):1521-5 [15501022.001]
  • [Cites] Life Sci. 1998;63(11):935-48 [9747894.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1931-41 [9815582.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):111-4 [9916802.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1299-307 [15520862.001]
  • [Cites] Ageing Res Rev. 2004 Nov;3(4):465-83 [15541712.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Aging Cell. 2004 Dec;3(6):379-89 [15569355.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Eur J Cell Biol. 2004 Dec;83(11-12):691-700 [15679113.001]
  • [Cites] Science. 2005 Feb 4;307(5710):720-4 [15618488.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):760-4 [15716955.001]
  • [Cites] Egypt J Immunol. 2004;11(1):1-8 [15724380.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3798-807 [15749921.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):867-74 [15471900.001]
  • [Cites] Nutr Cancer. 2005;51(2):197-206 [15860442.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4320-33 [15899824.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3940-7 [15867203.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Curr Mol Med. 2005 Mar;5(2):159-70 [15974869.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Mol Biol Cell. 2005 Jul;16(7):3323-33 [15872085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9194-9 [15967997.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Lancet. 2005 Jul 16-22;366(9481):249-60 [16023517.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):879-94 [15888687.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Mol Cell Endocrinol. 2005 Aug 30;240(1-2):11-22 [16005142.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):1048-52 [16107853.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):611-22 [16136653.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] J Neurosci. 2005 Sep 21;25(38):8680-5 [16177036.001]
  • [Cites] Physiol Rev. 2005 Oct;85(4):1373-416 [16183916.001]
  • [Cites] J Anat. 2005 Sep;207(3):197-208 [16185244.001]
  • [Cites] Int J Hematol. 2005 Oct;82(3):190-5 [16207589.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Plast Reconstr Surg. 2005 Nov;116(6):1686-96 [16267433.001]
  • [Cites] Trends Cell Biol. 2005 Dec;15(12):666-73 [16243526.001]
  • [Cites] Ann N Y Acad Sci. 2005 Dec;1057:479-91 [16399914.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:381-410 [16402910.001]
  • [Cites] Nat Rev Immunol. 2006 Feb;6(2):93-106 [16491134.001]
  • [Cites] PLoS Biol. 2006 Mar;4(3):e51 [16464125.001]
  • [Cites] Circulation. 2006 Mar 21;113(11):1451-63 [16549650.001]
  • [Cites] Pediatr Res. 2006 Apr;59(4 Pt 2):100R-3R [16549556.001]
  • [Cites] Nat Rev Neurosci. 2006 Apr;7(4):278-94 [16552414.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2680-5 [16332973.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Pathology. 2006 Apr;38(2):103-13 [16581649.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Nat Med. 2006 Apr;12(4):446-51 [16565722.001]
  • [Cites] Cell Oncol. 2006;28(1-2):3-29 [16675878.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):333-9 [16651378.001]
  • [Cites] Dev Biol. 2006 Jun 1;294(1):50-66 [16554047.001]
  • [Cites] PLoS Biol. 2006 Jun;4(6):e203 [16752948.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8822-7 [16723399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9226-31 [16754876.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1211-6 [16688229.001]
  • [Cites] Ann N Y Acad Sci. 2006 May;1067:323-31 [16804006.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1080-6 [16810243.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1516-8 [16754749.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jul;5(7):577-84 [16773071.001]
  • [Cites] Rejuvenation Res. 2006 Fall;9(3):402-7 [16859481.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):681-8 [16865285.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):338-46 [16877336.001]
  • [Cites] Ernst Schering Res Found Workshop. 2006;(60):81-98 [16903418.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):496-505 [16880792.001]
  • [Cites] Cancer Immunol Immunother. 2006 Dec;55(12):1553-64 [16491401.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Nature. 2006 Sep 28;443(7110):421-6 [16957735.001]
  • [Cites] Nature. 2006 Sep 28;443(7110):453-7 [16957737.001]
  • [Cites] Nature. 2006 Sep 28;443(7110):448-52 [16957738.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Novartis Found Symp. 2006;274:260-7; discussion 267-76 [17019817.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Exp Gerontol. 2006 Sep;41(9):828-36 [16942852.001]
  • [Cites] Cell. 2006 Oct 20;127(2):265-75 [17055429.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):34936-41 [16959784.001]
  • [Cites] Curr Drug Targets. 2006 Nov;7(11):1553-60 [17100594.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):997-1014 [17139285.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Nat Rev Genet. 2006 Dec;7(12):940-52 [17139325.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2840-50 [16945998.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] J Pathol. 2007 Jan;211(2):114-23 [17200948.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):81-92, ix [17244556.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1121-9 [17283146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2205-10 [17284601.001]
  • [Cites] J Cutan Pathol. 2007 Mar;34(3):247-56 [17302609.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1317-26 [17392301.001]
  • [Cites] Carcinogenesis. 2007 Apr;28(4):792-800 [17127714.001]
  • [Cites] J Transl Med. 2007;5:12 [17324292.001]
  • [Cites] Nat Cell Biol. 2007 Apr;9(4):470-8 [17369819.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1020-4 [17353922.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):818-27 [17420225.001]
  • [Cites] Mol Cancer. 2007;6:26 [17407576.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3716-24 [17440084.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):394-404 [17450177.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Circ Res. 2007 Apr 27;100(8):1116-27 [17463327.001]
  • [Cites] Exp Cell Res. 2007 May 15;313(9):1877-85 [17428472.001]
  • [Cites] EMBO Rep. 2007 May;8(5):497-503 [17396137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7 [17460043.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):361-70 [17517043.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):383-94 [17381549.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):371-82 [17381551.001]
  • [Cites] Exp Gerontol. 2007 Jun;42(6):463-71 [17507194.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):441-53 [17522713.001]
  • [Cites] Stem Cells. 2007 Jun;25(6):1478-89 [17332509.001]
  • [Cites] Nat Med. 2007 Jun;13(6):742-7 [17486088.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):686-90 [17554302.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:41-53 [17332071.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1013-20 [17640862.001]
  • [Cites] Trends Genet. 2007 Aug;23(8):413-8 [17559965.001]
  • [Cites] Science. 2007 Aug 10;317(5839):807-10 [17690295.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):703-13 [17717515.001]
  • [Cites] Behav Pharmacol. 2007 Sep;18(5-6):391-418 [17762509.001]
  • [Cites] Prog Brain Res. 2007;163:529-40 [17765736.001]
  • [Cites] Stem Cell Rev. 2007 Jan;3(1):30-8 [17873379.001]
  • [Cites] Cancer Biol Ther. 2007 May;6(5):763-8 [17592251.001]
  • [Cites] Cell Cycle. 2007 Sep 1;6(17):2148-51 [17786047.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Stem Cell Rev. 2007 Fall;3(3):201-11 [17917133.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63 [17911267.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Lab Invest. 2007 Nov;87(11):1071-6 [17767195.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2007 Jul-Sep;7(3):246-52 [17947808.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):277-90 [17954610.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17747-52 [17965232.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):837-47 [17999604.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10889-98 [18006834.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6549-54 [18006753.001]
  • [Cites] Expert Rev Mol Med. 2007;9(31):1-20 [18021462.001]
  • [Cites] Br J Pharmacol. 2007 Dec;152(7):1003-11 [17603541.001]
  • [Cites] Arch Dermatol Res. 2008 Jan;300(1):47-52 [17968567.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):1-11 [17980163.001]
  • [Cites] Biochimie. 2008 Jan;90(1):33-40 [18029083.001]
  • [Cites] Am J Kidney Dis. 2008 Jan;51(1):131-44 [18155543.001]
  • [Cites] Med Hypotheses. 2008;70(2):338-42 [17640824.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):110-9 [18175225.001]
  • [Cites] Nucleic Acids Res. 2007;35(22):7466-74 [17913742.001]
  • [Cites] Nucleic Acids Res. 2007;35(22):7557-65 [18160407.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):17-28; discussion 28-9 [17960465.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):345-9 [18202660.001]
  • [Cites] Aging Cell. 2008 Jan;7(1):23-31 [18028256.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):291-7 [18070208.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):380-7 [18219291.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1709-16 [17947508.001]
  • [Cites] Curr Stem Cell Res Ther. 2007 Jan;2(1):39-52 [18220891.001]
  • [Cites] Clin Interv Aging. 2007;2(4):605-10 [18225461.001]
  • [Cites] PLoS Genet. 2008 Jan;4(1):e10 [18208333.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):925-30 [18240351.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Mech Ageing Dev. 2008 Mar;129(3):163-73 [18241911.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):677-83 [18231105.001]
  • [Cites] Histol Histopathol. 2008 May;23(5):609-19 [18283646.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):167-79 [18256617.001]
  • [Cites] Cell. 2008 Feb 22;132(4):645-60 [18295581.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):283-94 [18278038.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1601-8 [18316625.001]
  • [Cites] Genes Dev. 2008 Mar 1;22(5):654-67 [18283121.001]
  • [Cites] Mol Med. 2008 Mar-Apr;14(3-4):167-74 [18224251.001]
  • [Cites] EMBO J. 2008 Mar 5;27(5):770-81 [18239686.001]
  • [Cites] Nat Med. 2008 Mar;14(3):306-14 [18297083.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Curr Pharm Des. 2008;14(6):562-73 [18336301.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1749-58 [17891174.001]
  • [Cites] Circ Res. 2008 Mar 14;102(5):597-606 [18202313.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1804-13 [18347183.001]
  • [Cites] BMC Neurosci. 2008;9:22 [18275610.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Ageing Res Rev. 2008 Apr;7(2):137-46 [18343732.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):452-9 [18311132.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):385-94 [18344989.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):162-8 [18391779.001]
  • [Cites] J Cell Biol. 2008 Apr 7;181(1):9-13 [18378774.001]
  • [Cites] Mech Ageing Dev. 2008 May;129(5):243-53 [18374391.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):557-79 [18391173.001]
  • [Cites] J Cell Mol Med. 2008 Apr;12(2):459-70 [18182066.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Panminerva Med. 2008 Mar;50(1):3-18 [18427384.001]
  • [Cites] Ann Plast Surg. 2008 May;60(5):538-44 [18434829.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Nat Clin Pract Oncol. 2008 May;5(5):280-90 [18349857.001]
  • [Cites] Blood. 2008 May 1;111(9):4446-55 [18239083.001]
  • [Cites] Blood. 2008 May 1;111(9):4523-31 [18310499.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2813-23 [18451249.001]
  • [Cites] Trends Cell Biol. 2008 May;18(5):228-35 [18346894.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 20;371(1):163-7 [18423378.001]
  • [Cites] Blood. 2008 May 15;111(10):5215-22 [18174376.001]
  • [Cites] Aging Cell. 2008 Jun;7(3):335-43 [18248663.001]
  • [Cites] Aging Cell. 2008 Jun;7(3):368-74 [18363905.001]
  • [Cites] Cancer Lett. 2008 Jun 28;265(1):124-34 [18343028.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):694-5 [18477795.001]
  • [Cites] Atherosclerosis. 2008 Jun;198(2):347-53 [17983621.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R25 [18366788.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):326-31 [18536570.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2846-53 [18539963.001]
  • [Cites] DNA Repair (Amst). 2008 Jul 1;7(7):1039-50 [18458003.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):244-50 [18534864.001]
  • [Cites] J Orthop Res. 2008 Jul;26(7):910-7 [18302252.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):535-42 [18568776.001]
  • [Cites] Mech Ageing Dev. 2008 Jul-Aug;129(7-8):460-6 [18462780.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Genome Biol. 2008;9(5):R83 [18492237.001]
  • [Cites] PLoS One. 2008;3(7):e2637 [18612434.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5533-9 [18632604.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6074-83 [18676829.001]
  • [Cites] PLoS One. 2008;3(8):e2935 [18698410.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):2042-51 [18499897.001]
  • [Cites] Aging Cell. 2008 Aug;7(4):590-8 [18462272.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Aug;21(4):457-63 [18627530.001]
  • [Cites] Genome Dyn. 2006;1:35-52 [18724052.001]
  • [Cites] Genome Dyn. 2006;1:218-42 [18724063.001]
  • [Cites] PLoS One. 2008;3(8):e3077 [18728788.001]
  • [Cites] Trends Cell Biol. 2008 Sep;18(9):421-9 [18715783.001]
  • [Cites] Antioxid Redox Signal. 2008 Nov;10(11):1883-94 [18627347.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):558-67 [18501520.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):419-27 [17965935.001]
  • [Cites] Gut. 2008 Oct;57(10):1456-68 [18791122.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7742-9 [18829528.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1155-63 [18470535.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Mol Cell Cardiol. 2008 Oct;45(4):582-92 [18396293.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):107-11 [18987743.001]
  • [Cites] DNA Repair (Amst). 2008 Dec 1;7(12):1973-81 [18786657.001]
  • [Cites] Mol Cell. 2008 Nov 7;32(3):306-12 [18995829.001]
  • [Cites] Mol Cell. 2008 Nov 7;32(3):313-24 [18995830.001]
  • [Cites] Mol Cell Biol. 2008 Dec;28(23):7225-35 [18809580.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1663-8 [18787416.001]
  • [Cites] Exp Gerontol. 2009 Jan-Feb;44(1-2):57-62 [18573328.001]
  • [Cites] Mech Ageing Dev. 2009 Jan-Feb;130(1-2):10-7 [18639575.001]
  • [Cites] Atherosclerosis. 2009 Feb;202(2):345-7 [18571177.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):465-73 [18680391.001]
  • (PMID = 19114129.001).
  • [ISSN] 1872-9649
  • [Journal-full-title] Ageing research reviews
  • [ISO-abbreviation] Ageing Res. Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA133774; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / R01 CA133774; United States / NCI NIH HHS / CA / CA131944; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 212
  • [Other-IDs] NLM/ NIHMS526851; NLM/ PMC3828651
  •  go-up   go-down


40. Schwer AL, Kavanagh BD, McCammon R, Gaspar LE, Kleinschmidt-De Masters BK, Stuhr K, Chen C: Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2009 Apr 1;73(5):1352-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
  • PURPOSE: To describe the radiographic and histopathologic changes after stereotactic radiosurgery (SRS) and epidermal growth factor receptor inhibition in patients with recurrent malignant gliomas.
  • METHODS AND MATERIALS: A total of 15 patients with recurrent high-grade gliomas were treated on a prospective Phase I trial combining SRS and gefitinib.
  • Serial brain magnetic resonance imaging scans were analyzed to characterize the volumetric changes in the T(1)C and T(2) abnormalities after treatment.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Male. Middle Aged. Prospective Studies. Quinazolines / therapeutic use. Radiosurgery / methods. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013723.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


41. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol; 2009 Jan;91(2):183-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
  • This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic glioma when treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC).
  • Treatment with poly-ICLC continued until tumor progression.
  • Ten were ineligible after central review of pathology.
  • Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 [18262679.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Immunology. 2008 Aug;124(4):480-8 [18248388.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Interferon Res. 1982;2(1):1-4 [6180095.001]
  • [Cites] Tex Rep Biol Med. 1981-1982;41:653-62 [6189230.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1058-65 [3155990.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2483-91 [2411797.001]
  • [Cites] J Biol Response Mod. 1985 Oct;4(5):475-80 [2416882.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):640-9 [2418162.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):664-8 [2418164.001]
  • [Cites] Gynecol Oncol. 1986 Jul;24(3):359-61 [3721308.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1341-2 [3768878.001]
  • [Cites] J Urol. 1987 Feb;137(2):202-6 [3806804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3005-10 [1591717.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):120-6 [1318961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):75-83 [7721642.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Methods Mol Biol. 2007;383:277-301 [18217692.001]
  • (PMID = 18850068.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062421-08; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; 9004-32-4 / Carboxymethylcellulose Sodium
  • [Other-IDs] NLM/ NIHMS291833; NLM/ PMC3104130
  •  go-up   go-down


42. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand; 2008 Mar;117(3):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.
  • Materials and Methods - Boron uptake in recurrent GBM was measured for four patients.
  • BNCT was well tolerated and quality of life remained stable until tumor progression for all 12 patients.
  • No correlation was found between survival times and minimum tumor dose and number of radiation fields.
  • Conclusions - Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Body Weight. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297764.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Lee VH, Connolly HM, Brown RD Jr: Central nervous system manifestations of cardiac myxoma. Arch Neurol; 2007 Aug;64(8):1115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system manifestations of cardiac myxoma.
  • Prompt diagnosis is of paramount significance to prevent recurrent complications.
  • Potential delayed neurologic complications relevant to patients with tumor embolization include myxoma-induced cerebral aneurysm and myxomatous metastasis, which can mimic the clinical picture of central nervous system vasculitis or infective endocarditis.
  • [MeSH-major] Brain Diseases / etiology. Heart Neoplasms / complications. Myxoma / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiography. Echocardiography, Transesophageal. Female. Heart Atria. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698701.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Twenty-five patients (15 men; 10 women) ages 26-63 (median 50), with radiographically recurrent AA were treated.
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator refractory AA.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


45. Ahmadi R, Dictus C, Hartmann C, Zürn O, Edler L, Hartmann M, Combs S, Herold-Mende C, Wirtz CR, Unterberg A: Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir (Wien); 2009 Nov;151(11):1359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients.
  • PATIENTS AND METHODS: In the present study, we performed an analysis on data of 130 adult low-grade glioma patients.
  • Re-surgery in the case of a tumor relapse has a significant impact on OS and PFS, too.
  • CONCLUSIONS: In summary, we could retrospectively evaluate a large case series of well-defined low-grade gliomas patients with a long follow-up period showing that extended surgery would be the most effective therapy for low-grade glioma patients even in recurrent diseases.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioma / mortality. Glioma / surgery. Neurosurgical Procedures / methods. Neurosurgical Procedures / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Combined Modality Therapy / methods. Combined Modality Therapy / statistics & numerical data. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Monitoring, Intraoperative. Neoplasm Invasiveness / physiopathology. Neoplasm Invasiveness / prevention & control. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Neuronavigation. Preoperative Care. Prognosis. Radiotherapy / methods. Radiotherapy / statistics & numerical data. Retrospective Studies. Stereotaxic Techniques. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Neurochir (Wien). 2009 Nov;151(11):1367. Rezvan, Ahmadi [corrected to Ahmadi, Rezvan]; Christine, Dictus [corrected to Dictus, Christine]; Christian, Hartmann [corrected to Hartmann, Christian]; Olga, Zürn [corrected to Zürn, Olga]; Lutz, Edler [corrected to Edler, Lutz]; Marius, Hartmann [corrected to Hartmann, Marius]; Stephanie, Combs [corrected to Combs, Stephanie]; Christel, Herold-Mende [corrected to Herold-Mende, Christel]; Rainer, Wirtz Christian [corrected to Wirtz, Christian Rainer]; Andreas, Unterberg [corrected to Unterberg, Andreas]
  • (PMID = 19575144.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


46. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, Schramm J, Wiestler OD, Lichter P, Reifenberger G: Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene; 2007 Feb 15;26(7):1088-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood.
  • Other recurrent losses affected chromosomes 17 (10%), 8, 18, 22 (4% each).
  • Recurrent gains were identified on chromosomes X (16%), 7, 9q, 20 (8% each), 4, 5, 19 (4% each).
  • Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions.
  • [MeSH-major] Astrocytoma / genetics. Chromosome Deletion. Chromosomes, Human, Pair 9 / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Deletion. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / deficiency
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Homozygote. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Chromosome 9.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909113.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein
  •  go-up   go-down


47. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102 Suppl:75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The lesions were primary in 86% and recurrent 14% of the cases; they were solitary in 31%, single in 29%, and multiple in 40%.
  • The 1-year local tumor control rate was 94%.
  • CONCLUSIONS: Gamma knife surgery is a useful treatment for brain metastases from NSCLC.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Radiation Dosage. Retrospective Studies. Time


48. Lozier AP, Arbaje YM, Scheithauer BW: Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report. Neurosurgery; 2009 Oct;65(4):E816-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report.
  • OBJECTIVE: Choroid plexus carcinoma (CPCa) is an uncommon tumor rarely occurring in patients older than 2 years of age.
  • The case reported herein represents the first documented example of a primary supratentorial, extraventricular CPCa in an adult.
  • INTERVENTION: The tumor was gross-totally removed via a frontotemporal craniotomy.
  • A magnetic resonance imaging scan 44 months after surgery showed no evidence of residual or recurrent tumor.
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Brain / physiopathology. Brain / surgery. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Administration Schedule. Female. Humans. Lateral Ventricles / pathology. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834361.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


49. Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W, Fiedler VU, Niehoff H, Ulrich SD, Yang Q, Ulrich F: MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur J Radiol; 2006 Aug;59(2):208-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
  • We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent glioblastoma multiforme.
  • The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation.
  • We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Laser Coagulation. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Temperature
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854549.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


50. Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ: Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol; 2007 Jan;9(1):70-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
  • The purpose of this study was to determine the efficacy and tolerability of Cloretazine in patients with recurrent glioblastoma multiforme.
  • Patients with recurrent glioblastoma multiforme received Cloretazine (300 mg/m(2)) intravenously every six weeks.
  • Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Dec;15(6):1027-52 [11770297.001]
  • [Cites] Clin Oncol. 1978 Mar;4(1):71-6 [346276.001]
  • [Cites] Cancer Clin Trials. 1979 Spring;2(1):43-8 [229983.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):38-44 [6321671.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):218-23 [2991486.001]
  • [Cites] Semin Oncol. 1986 Mar;13(1):38-45 [3513316.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • [Cites] Biochem Pharmacol. 2005 May 15;69(10):1463-72 [15857610.001]
  • [Cites] Carcinogenesis. 1984 Jan;5(1):121-4 [6690082.001]
  • (PMID = 17108065.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA096890; United States / NCI NIH HHS / CA / 1 P20 CA096890
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1828104
  •  go-up   go-down


51. Smith JS, Cha S, Mayo MC, McDermott MW, Parsa AT, Chang SM, Dillon WP, Berger MS: Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg; 2005 Sep;103(3):428-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.
  • OBJECT: Diffusion-weighted magnetic resonance (MR) imaging is an invaluable tool in the diagnosis of acute stroke and other types of brain injury.
  • Findings on neuroimaging during the period of enhancement could be confused with recurrent tumor and interpreted as early treatment failure.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Diffusion Magnetic Resonance Imaging. Glioma / diagnosis. Glioma / surgery. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Postoperative Complications / diagnosis. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235673.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS045013
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


52. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


53. Chua DT, Wu SX, Lee V, Tsang J: Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis. Head Neck Oncol; 2009;1:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were individually matched for failure type (persistent or recurrent), rT stage (rT1-2 or rT3-4), and tumor volume (< or = 5 cc, >5-10 cc, or >10 cc).
  • The differences in local control were mainly observed in recurrent or rT2-4 disease.
  • Incidence of severe late complications was 33% in SRS group vs. 21% in SRM group, including brain necrosis (16% vs. 12%) and hemorrhage (5% vs. 2%).
  • CONCLUSION: Our study showed that SRM was superior to SRS in salvaging local failures of NPC, especially in the treatment of recurrent and rT2-4 disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Oct;53(1):23-8 [10624849.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):761-9 [17601682.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Feb;33(2):91-8 [10737370.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):405-12 [10802367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):501-5 [10974468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):717-26 [11395240.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):255-8 [11404496.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):164-70 [11516866.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2845-55 [11753958.001]
  • [Cites] Head Neck. 2002 Aug;24(8):748-53 [12203799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):413-26 [12738316.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):682-7 [14967420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):388-94 [15380570.001]
  • [Cites] Acta Radiol Oncol. 1983;22(1):23-8 [6305129.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):953-6 [3597157.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):505-12 [8382202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):773-82 [8344845.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):14-9 [7883544.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):997-1003 [9169805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):43-52 [9212003.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):977-81 [9392534.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):18-22 [9499250.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):897-913 [9531376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):379-86 [9607354.001]
  • [Cites] Laryngoscope. 1999 May;109(5):805-9 [10334235.001]
  • [Cites] Head Neck. 2004 Dec;26(12):1024-30 [15390194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16 [15752890.001]
  • [Cites] Head Neck. 2005 Jul;27(7):555-65 [15880410.001]
  • [Cites] Radiother Oncol. 2005 May;75(2):197-203 [15876464.001]
  • [Cites] Radiother Oncol. 2005 Dec;77(3):290-4 [16289398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1415-21 [17056191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):469-74 [17869663.001]
  • [Cites] Radiother Oncol. 2000 Feb;54(2):135-42 [10699476.001]
  • (PMID = 19463191.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2694191
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


54. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
  • Patients with recurrent malignant glioma received oral atrasentan at >or=10 mg/day.
  • Patients were evaluated for response every 8 weeks and remained on the study until the tumor progressed or toxicities occurred.
  • We conclude that the MTD of daily oral atrasentan in patients with recurrent malignant glioma is 70 mg/day.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


55. Mitsuya K, Nakasu Y, Horiguchi S, Harada H, Nishimura T, Bando E, Okawa H, Furukawa Y, Hirai T, Endo M: Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol; 2010 Aug;99(1):81-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery.
  • After stereotactic radiosurgery (SRS) for brain metastases, delayed radiation effects with mass effect may occur from several months to years later, when tumors may also recur.
  • Conventional magnetic resonance (MR) imaging does not provide sufficient information to differentiate delayed radiation effects from tumor recurrence.
  • Positron emission tomography, MR spectroscopy, and other modalities sometimes may lead to false findings of tumor recurrence.
  • Twenty-eight lesions were enlarged on serial MR images in 27 patients 2-35 months (median: 11.8 months) after SRS for metastatic brain tumors.
  • To calculate the relative cerebral blood volume ratio (rCBV ratio), the regions of interest were located in the enhanced areas on the contrast-enhanced T1-weighted images and compared with the corresponding contralateral normal brain tissue.
  • An rCBV ratio of greater than 2.1 provided the best sensitivity and specificity for identifying recurrent metastatic tumors, at 100 and 95.2%, respectively.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Magnetic Resonance Angiography / methods. Neoplasm Recurrence, Local / etiology. Radiation Injuries / etiology. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cerebrovascular Circulation / physiology. Contrast Media. Female. Humans. Male. Middle Aged. Prospective Studies. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1994 Dec;163(6):1459-65 [7992747.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):773-81 [16937146.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Neuroimaging Clin N Am. 1999 May;9(2):309-31 [10318717.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):496-520 [11276094.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):163-71 [8699239.001]
  • [Cites] Radiology. 2002 Dec;225(3):871-9 [12461273.001]
  • [Cites] Neurosurgery. 2007 Oct;61(4):778-86; discussion 786-7 [17986939.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Magn Reson Med. 1990 May;14(2):249-65 [2345506.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Feb;30(2):367-72 [19022867.001]
  • [Cites] J Nucl Med. 2008 May;49(5):694-9 [18413375.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):600-9 [17886561.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] Minim Invasive Neurosurg. 2005 Aug;48(4):228-34 [16172969.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Aug;34(8):534-7 [7526239.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):901-9 [10815666.001]
  • [Cites] Invest Radiol. 2004 May;39(5):277-87 [15087722.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):853-8 [16611778.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Clin Imaging. 2008 Jul-Aug;32(4):251-8 [18603178.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 [15502131.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):533-40 [14585263.001]
  • [Cites] J Neurol. 2009 Jun;256(6):878-87 [19274425.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10):1981-7 [17893216.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):96-100 [12483415.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):266-271 [28306470.001]
  • (PMID = 20058049.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


56. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P, Gruber ML: Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has shown promise in the treatment of patients with recurrent high-grade glioma.
  • Changes in relative cerebral blood volume, perfusion-permeability index, and tumor volume measurement were measured to assess the therapeutic response.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms. Dacarbazine / analogs & derivatives. Glioma
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Blood Volume / drug effects. Cerebrovascular Circulation / drug effects. Combined Modality Therapy / methods. Feasibility Studies. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Vascular Endothelial Growth Factor Receptor-2 / analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793954.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


57. Kanamori M, Kumabe T, Saito R, Yamashita Y, Sonoda Y, Tominaga T: [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. No Shinkei Geka; 2010 Nov;38(11):997-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The adverse effects of combination chemotherapy of ifosfamide, cisplatin, and etoposide (ICE) were evaluated in the treatment of various intracranial brain tumors.
  • The histological diagnosis was newly diagnosed or recurrent germ cell tumor in 45 cases, medulloblastoma in 19, primitive neuroectodermal tumor (PNET) in 7, anaplastic ependymoma in 6, recurrent glioblastoma in 13, and others in 18 cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Ependymoma / drug therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Glioblastoma / drug therapy. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Infant. Male. Medulloblastoma / drug therapy. Middle Aged. Neoplasms, Germ Cell and Embryonal / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081811.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


58. Bartsch R, Weitmann HD, Pennwieser W, Wenzel C, Muschitz S, Baldass M, Hassler M, Marosi C, Rössler K, Pötter R, Dieckmann K: Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien Klin Wochenschr; 2005 Dec;117(23-24):821-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignant gliomas are brain tumors deriving from the brain's glia cells.
  • We evaluated the safety and efficacy of re-irradiation in patients with recurrent malignant glioma.
  • PATIENTS AND METHODS: Twenty-two patients were treated with a second irradiation for recurrent or progressive glioma.
  • Patients either received hypo-fractionated stereotactic treatment or conventionally fractionated conformal therapy, depending on tumor size.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / radiotherapy. Glioma / mortality. Glioma / radiotherapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Austria / epidemiology. Child. Feasibility Studies. Female. Humans. Incidence. Male. Middle Aged. Radiosurgery / statistics & numerical data. Radiotherapy, Adjuvant / statistics & numerical data. Radiotherapy, Conformal / statistics & numerical data. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437319.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


59. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNAB) of the cervical lymph node prior to neck dissection suggested a possible metastatic primitive neuroepithelial tumor.
  • In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix R, Jordan A: Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol; 2007 Jan;81(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to evaluate the feasibility and tolerability of the newly developed thermotherapy using magnetic nanoparticles on recurrent glioblastoma multiforme.
  • The actually achieved magnetic fluid distribution was measured by computed tomography (CT), which after matching to pre-operative MRI data enables the calculation of the expected heat distribution within the tumor in dependence of the magnetic field strength.
  • Patients received 4-10 (median: 6) thermotherapy treatments following instillation of 0.1-0.7 ml (median: 0.2) of magnetic fluid per ml tumor volume and single fractions (2 Gy) of a radiotherapy series of 16-70 Gy (median: 30).
  • Median maximum intratumoral temperatures of 44.6 degrees C (42.4-49.5 degrees C) were measured and signs of local tumor control were observed.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy. Hyperthermia, Induced / methods. Nanoparticles / therapeutic use. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Magnetics / therapeutic use. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer J. 2003 May-Jun;9(3):180-8 [12952303.001]
  • [Cites] IEEE Trans Biomed Eng. 1994 Feb;41(2):97-107 [8026856.001]
  • [Cites] Int J Hyperthermia. 1993 Jan-Feb;9(1):51-68 [8433026.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95 [9457811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):289-97 [8420877.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):371-80 [9308941.001]
  • [Cites] Prostate. 2005 Aug 1;64(3):283-92 [15726645.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Int J Hyperthermia. 2003 May-Jun;19(3):267-94 [12745972.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800 [6547421.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56 [12098606.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Cancer Invest. 1996;14(6):551-9 [8951359.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Prostate. 2006 Jan 1;66(1):97-104 [16114060.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3079-85 [15860867.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):242-8; discussion 242-8 [15670372.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):487-97 [12147435.001]
  • [Cites] Int J Hyperthermia. 1997 Nov-Dec;13(6):587-605 [9421741.001]
  • [Cites] Int J Hyperthermia. 2004 Aug;20(5):451-63 [15277019.001]
  • [Cites] Int J Hyperthermia. 1998 Mar-Apr;14(2):125-33 [9589319.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 1989 Oct;165(10):751-7 [2814816.001]
  • (PMID = 16773216.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Drzymala RE, Wasserman TH, Won M, Shaw E, Cmelak AJ, Loeffler J, Souhami L, Radiation Therapy Oncology Group: A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). Radiother Oncol; 2008 Apr;87(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
  • Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation.
  • The toxicity is reported in three groups of patients according to the tumor size.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Etanidazole / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Radiosurgery / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342381.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 30DKA3Q1HL / Etanidazole
  •  go-up   go-down


62. Kalani MY, Filippidis AS, Kalani MA, Sanai N, Brachman D, McBride HL, Shetter AG, Smith KA: Gamma Knife surgery combined with resection for treatment of a single brain metastasis: preliminary results. J Neurosurg; 2010 Dec;113 Suppl:90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery combined with resection for treatment of a single brain metastasis: preliminary results.
  • OBJECT: Resection and whole-brain radiation therapy (WBRT) have classically been the standard treatment for a single metastasis to the brain.
  • The objective of this study was to evaluate the use of Gamma Knife surgery (GKS) as an alternative to WBRT in patients who had undergone resection and to evaluate patient survival and local tumor control.
  • In 45 patients (66.2%) there was systemic control of the primary tumor when the cranial metastasis was identified.
  • During the follow-up period we identified 27 patients (39.7%) with recurrent tumor located either local or distant to the site of treatment.
  • CONCLUSIONS: Although the debate about the ideal form of radiation treatment after resection continues, these findings indicate that GKS combined with surgery offers comparable survival duration and local tumor control to WBRT for patients with a diagnosis of a single metastasis.
  • [MeSH-major] Brain / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121791.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res; 2007 Apr 01;13(7):2038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
  • Recently, inactivating mutations in the mismatch repair gene MSH6 were identified in two glioblastomas recurrent post-temozolomide.
  • RESULTS: MSH6 mutation was not observed in any pretreatment glioblastoma (0 of 40), whereas 3 of 14 recurrent cases had somatic mutations (P = 0.015).
  • Measurements of in vivo tumor growth using three-dimensional reconstructed magnetic resonance imaging showed that MSH6-negative glioblastomas had a markedly increased rate of growth while under temozolomide treatment (3.17 versus 0.04 cc/mo for MSH6-positive tumors; P = 0.020).
  • CONCLUSIONS: Loss of MSH6 occurs in a subset of post-XRT + temozolomide glioblastoma recurrences and is associated with tumor progression during temozolomide treatment, mirroring the alkylator resistance conferred by MSH6 inactivation in vitro.
  • MSH6 deficiency may therefore contribute to the emergence of recurrent glioblastomas during temozolomide treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Brain Neoplasms / genetics. DNA-Binding Proteins / drug effects. DNA-Binding Proteins / genetics. Dacarbazine / analogs & derivatives. Glioblastoma / genetics
  • [MeSH-minor] Adult. Aged. Cell Proliferation / drug effects. DNA Modification Methylases / biosynthesis. DNA Modification Methylases / drug effects. DNA Repair Enzymes / biosynthesis. DNA Repair Enzymes / drug effects. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local / genetics. Polymerase Chain Reaction. Tumor Suppressor Proteins / biosynthesis. Tumor Suppressor Proteins / drug effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):333-40 [15662974.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1851-60 [15872200.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4525-9 [15930269.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4689-93 [16000562.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6394-400 [16024643.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):335-46 [16612326.001]
  • [Cites] Mol Cell. 2006 May 19;22(4):501-10 [16713580.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2751-63 [16807412.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2908-17 [10537360.001]
  • [Cites] Mutat Res. 2000 May 30;450(1-2):125-38 [10838138.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3262-70 [10866320.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5770-5 [11296254.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):1959-66 [11972333.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):661-8 [12538819.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):161-71 [14679137.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1262-9 [15098177.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3391-4 [15150090.001]
  • [Cites] Nature. 2004 Jun 24;429(6994):891-5 [15215866.001]
  • [Cites] Oncology. 2004;66(5):395-403 [15331927.001]
  • [Cites] Fam Cancer. 2004;3(2):123-7 [15340263.001]
  • [Cites] Nature. 1993 Apr 15;362(6421):652-4 [8464518.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6424-8 [8341649.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3721-5 [7641183.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5375-9 [8968088.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3949-55 [9307278.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):373-82 [10190549.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):807-14 [10213216.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10764-9 [10485900.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 17404084.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2873832; NLM/ UKMS30573
  •  go-up   go-down


64. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors.
  • Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


65. Uesaka T, Shono T, Suzuki SO, Nakamizo A, Niiro H, Mizoguchi M, Iwaki T, Sasaki T: Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol; 2007 Jul;83(3):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis in various brain tumors.
  • We found that these tumors expressed significant amounts of VEGF mRNA in comparison with other brain tumors, including malignant gliomas and meningiomas.
  • The expression levels of VEGF and VEGFR-1 mRNA in recurrent tumors were higher than those in primary tumors.
  • When we divided patients into two groups according to VEGF mRNA expression in the tumor, there was no significant difference in patient age, gender, or cranial nerves of origin between groups; however, the tumor volume tended to be larger in the high VEGF group than in the low VEGF group.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neurilemmoma / genetics. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor Receptor-1 / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Cranial Nerve Neoplasms / genetics. Cranial Nerve Neoplasms / metabolism. Cranial Nerve Neoplasms / pathology. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunoenzyme Techniques. Male. Meningioma / genetics. Meningioma / metabolism. Meningioma / pathology. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neurofibromin 2 / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Ubiquitin-Protein Ligases / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Nat Med. 2000 Apr;6(4):405-13 [10742147.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2129-34 [14660915.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):99-103 [16193379.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(6):763-70 [8836295.001]
  • [Cites] Otol Neurotol. 2002 Sep;23(5):736-48 [12218628.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] Acta Otolaryngol. 2003 Dec;123(9):1040-5 [14710905.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):635-41 [10682677.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Clin Neuropathol. 2003 Jan-Feb;22(1):30-4 [12617191.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):86-92 [15699725.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):949-55 [9833821.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):98-101 [15699727.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):35-40 [10982008.001]
  • [Cites] J Neurooncol. 2001 Nov;55(2):91-100 [11817706.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • (PMID = 17570036.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Neurofibromin 2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


66. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA: Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol; 2008 Sep;89(2):179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
  • BACKGROUND: Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy.
  • PURPOSE: The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Analysis. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Jun 15;63(12 ):3133-7 [12810640.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] N Engl J Med. 2000 May 11;342(19):1416-29 [10805828.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):176-84 [12744471.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurology. 2006 Feb 14;66(3):427-9 [16476947.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Forum (Genova). 2003;13(1):4-17 [14732884.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4758-63 [16966689.001]
  • [Cites] Oncology (Williston Park). 1989 Jul;3(7):43-9; discussion 51-3 [2701811.001]
  • [Cites] Biochemistry. 1994 Aug 9;33(31):9045-51 [8049205.001]
  • [Cites] Ann Neurol. 2006 Dec;60(6):740-3 [17192931.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):322-6 [16049942.001]
  • (PMID = 18431544.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


67. Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol; 2010 Aug;99(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bevacizumab is an anti-vascular endothelial growth factor (VEGF) antibody with activity against recurrent malignant glioma inducing high rates of objective responses as assessed by magnetic resonance imaging (MRI).
  • However, the mechanisms of the anti-tumor action of bevacizumab are controversial.
  • Vascular normalization with hyperperfusion and enhanced oxygen delivery to the tumor has been suggested as an alternative mechanism.
  • We analyzed diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps in 18 consecutive patients with recurrent malignant glioma before and after exposure to bevacizumab.
  • Stroke-like lesions with diffusion restriction on DWI and corresponding ADC decrease were induced by bevacizumab within the previously enhancing tumor area in 13 of 18 patients.
  • In one patient, an ADC-decreased lesion was biopsied, and histology showed atypical necrosis and nuclear hypoxia-inducible factor 1alpha upregulation but no tumor recurrence.
  • Within the tumor bed, bevacizumab induces diffusion-restricted lesions in the presence of reduced rCBF and rCBV.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Brain Neoplasms / pathology. Glioma / drug therapy. Glioma / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Bevacizumab. Cerebrovascular Circulation / physiology. Diffusion Magnetic Resonance Imaging / methods. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2008 Oct;10(5):700-8 [18697955.001]
  • [Cites] Radiology. 2009 Jul;252(1):182-9 [19561256.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5565-70 [11034104.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):715-25 [8916022.001]
  • [Cites] Acta Radiol. 2009 Jul;50(6):682-9 [19449234.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Magn Reson Imaging. 2006 Nov;24(9):1131-42 [17071335.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Brain. 2009 Jun;132(Pt 6):1509-22 [19416948.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Cancer Sci. 2007 May;98 (5):674-84 [17355261.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):60-4 [11158889.001]
  • (PMID = 20035366.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


68. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res; 2006 Aug 15;12(16):4899-907
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Piperazines / adverse effects. Piperazines / therapeutic use. Pyrimidines / adverse effects. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Anticonvulsants / therapeutic use. Benzamides. Drug Interactions. Female. Genotype. Humans. Imatinib Mesylate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914578.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03CA102974-02
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Spreafico F, Gandola L, Marchianò A, Simonetti F, Poggi G, Adduci A, Clerici CA, Luksch R, Biassoni V, Meazza C, Catania S, Terenziani M, Musumeci R, Fossati-Bellani F, Massimino M: Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain tumors. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1011-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain tumors.
  • PURPOSE: Brain necrosis or other subacute iatrogenic reactions has been recognized as a potential complication of radiotherapy (RT), although the possible synergistic effects of high-dose chemotherapy and RT might have been underestimated.
  • METHODS AND MATERIALS: We reviewed the clinical and radiologic data of 49 consecutive children with malignant brain tumors treated with high-dose thiotepa and autologous hematopoietic stem cell rescue, preceded or followed by RT.
  • RESULTS: Of the 49 children, 18 (6 of 25 with high-grade gliomas and 12 of 24 with primitive neuroectodermal tumors) had abnormal brain MRI findings occurring a median of 8 months (range, 2-39 months) after RT and beginning to regress a median of 13 months (range, 2-26 months) after onset.
  • Such findings pose a major diagnostic challenge in terms of their differential diagnosis vis-à-vis recurrent tumor.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Brain. Brain Neoplasms. Glioma. Neuroectodermal Tumors, Primitive. Thiotepa / adverse effects
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cognition / drug effects. Cognition / radiation effects. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Infant. Intelligence / drug effects. Intelligence / radiation effects. Magnetic Resonance Imaging. Male. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904307.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


70. Lonjon N, Bauchet L, Duffau H, Fabbro-Peray P, Segnarbieux F, Paquis P, Lonjon M: [Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review]. Neurochirurgie; 2010 Feb;56(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Glioblastoma, the most common malignant primary brain tumor in adults, is usually rapidly fatal.
  • If the tumor is symptomatic for mass effect, repeated surgery may be proposed.
  • All patients who underwent a second resection for recurrent glioblastoma were included.
  • CONCLUSIONS: The effect of resection of recurrent glioblastoma on survival has not been extensively studied.
  • Selected patients with recurrent glioblastoma may be candidates for repeated surgery when the situation appears favorable based on assessment of the individual patient's factors.
  • Factors such medical history, neurological status, location of the tumor, and progression-free survival have been proven in retrospective studies to give better results.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Glioblastoma / pathology. Glioblastoma / surgery. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20045159.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 26
  •  go-up   go-down


71. Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Mäcke H, Müller-Brand J, Merlo A: Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study. J Neurooncol; 2010 Oct;100(1):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete surgical resection beyond tumor margins cannot be achieved in glioblastoma multiforme (GBM) because of infiltrative nature.
  • In several cancers, neoadjuvant treatment has been implemented to reduce the risk of tumor cell spreading during resection.
  • In GBM, the objective of a neoadjuvant approach is reduction of tumor cells within the main tumor mass and beyond in the infiltration zone.
  • In a previous study with recurrent gliomas, we showed that local intratumoral injection of radiolabeled DOTAGA-substance P substantially inhibited further growth and led to radionecrotic transformation of the tumor (CCR 2006).
  • The high extent of resection and concomitant irradiation of tumor cells in the infiltration zone may be prognostically relevant.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Heterocyclic Compounds, 1-Ring / therapeutic use. Neoadjuvant Therapy / methods. Substance P / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diagnostic Imaging / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Organometallic Compounds. Radiopharmaceuticals / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2157-65 [10873064.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(5):303-20 [10591819.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Expert Rev Neurother. 2006 Aug;6(8):1199-209 [16893347.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3843-50 [16778112.001]
  • [Cites] Adv Tech Stand Neurosurg. 2004;29:229-63 [15035340.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1388-95 [17265035.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1021-34 [16897272.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3862-72 [11078500.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1004-11 [15597761.001]
  • [Cites] Neurosurg Focus. 2005 Apr 15;18(4):e12 [15844864.001]
  • [Cites] Oncologist. 2006 Jun;11(6):574-89 [16794237.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Cancer. 1997 May 29;71(5):810-6 [9180150.001]
  • [Cites] Ernst Schering Res Found Workshop. 2005;(49):43-72 [15524210.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):786-92 [7790112.001]
  • [Cites] Neurosurg Clin N Am. 2005 Jan;16(1):xi-xiii [15561527.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):486-93 [11914886.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1025-33 [10353735.001]
  • [Cites] Breast. 2006 Feb;15 Suppl 1:S3-13 [16500235.001]
  • [Cites] Neuro Oncol. 2008 Apr;10 (2):216-22 [18314417.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):937-49 [17171643.001]
  • [Cites] Int J Rehabil Res. 2005 Jun;28(2):135-9 [15900183.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):391-5 [12968806.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:57-61 [11143263.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6 [18496181.001]
  • [Cites] J Gene Med. 2004 Aug;6(8):937-47 [15293352.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 20217458.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 1-Ring; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 0 / substance P, 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-arginyl(1)-; 33507-63-0 / Substance P
  •  go-up   go-down


72. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: As in all diffuse gliomas, recurrence is an inherent feature of oligodendrogliomas, either as the same or higher grade neoplasm at the primary site.
  • The rate of remote recurrence after surgery for the primary tumor cannot be estimated from the scarce literature, but delayed treatment of the primary tumor and genetic alterations may be associated with this phenomenon.
  • The genetic analysis of the primary and recurrent tumors showed trisomy 7, monosomy 10, but not 1p or 19q deletions, which have been proposed as markers for favorable prognosis.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF, Children's Oncology Group: A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer; 2007 Dec 1;110(11):2535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
  • BACKGROUND: An open-label Phase II study of tipifarnib was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), high-grade glioma (HGG), and diffuse intrinsic brainstem glioma (BSG).
  • METHODS: Between January 2004 and July 2005, patients were enrolled and stratified as follows: Stratum 1, recurrent or refractory MB/PNET; Stratum 2, recurrent or refractory HGG; and Stratum 3, recurrent or refractory BSG.
  • CONCLUSIONS: Tipifarnib tolerated well but had little activity as a single agent in children with recurrent central nervous system malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Medulloblastoma / drug therapy. Quinolones / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Neuroectodermal Tumors / drug therapy. Treatment Outcome


74. Kalapurakal JA, Goldman S, Stellpflug W, Curran J, Sathiaseelan V, Marymont MH, Tomita T: Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):800-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy).
  • PURPOSE: To describe the preliminary results after intraoperative radiotherapy (IORT) with the photon radiosurgery system in children with recurrent brain tumors treated at the first dose level (10 Gy) of a Phase I protocol.
  • METHODS AND MATERIALS: A Phase I IORT dose escalation protocol was initiated at Children's Memorial Hospital to determine the maximal tolerated IORT dose in children with recurrent brain tumors.
  • Eight patients (57%) had tumor control within the surgical bed after IORT.
  • CONCLUSION: Our findings have demonstrated the safety and feasibility of IORT to a dose of 10 Gy to 2 mm in children with previously irradiated brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Photons / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Brain / radiation effects. Child. Ependymoma / radiotherapy. Ependymoma / surgery. Feasibility Studies. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Necrosis / etiology. Radiation Injuries / etiology. Radiosurgery / instrumentation. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580791.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Secondino S, Citterio A, Pedrazzoli P, Funaioli C, Scialfa GG, Siena S: Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. Anticancer Res; 2008 Nov-Dec;28(6B):3991-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
  • We report on radiological abnormalities resembling recurrent tumor in adult medulloblastoma receiving intensified chemotherapy and radiotherapy.
  • Evidence provided in this paper confirms previous reports in the pediatric population and suggests that neuroradiologist and medical oncologists should be aware of new possible radiological findings related to aggressive treatments for brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192661.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


76. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol; 2005 Feb;71(3):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PATIENTS AND METHODS: Adult patients with radiographic evidence of recurrent or progressive tumor following primary therapy were eligible for study.
  • CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.
  • The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Disease-Free Survival. Drug Resistance, Neoplasm / drug effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leukopenia / chemically induced. Male. Middle Aged. Paclitaxel / administration & dosage. Recombinant Proteins. Thrombocytopenia / chemically induced. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6 [12095566.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Oncologist. 2003;8(1):76-82 [12604734.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1964-5 [8656268.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):923-7 [11521796.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1893-900 [11283120.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):725-7 [8428353.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2230-7 [7545219.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96 [11592339.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20 [1331485.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2032-7 [9626200.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2066-71 [7636549.001]
  • [Cites] Biometrics. 1993 Sep;49(3):741-52 [8241370.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):539-43 [8120551.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):600-9 [8636777.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Expert Opin Pharmacother. 2001 Mar;2(3):491-505 [11336601.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9 [11516860.001]
  • (PMID = 15735921.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


77. Iacob G, Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life; 2009 Oct-Dec;2(4):386-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors.
  • Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature.
  • Therapeutic attitude in recurrent GBM is also widely discussed.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chromosome Mapping. Diagnosis, Differential. Gene Amplification. Humans. Middle Aged. Mutation. Oncogenes. PTEN Phosphohydrolase / deficiency. PTEN Phosphohydrolase / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Sep;3(9):E1 [17805242.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Hum Gene Ther. 2003 Sep 1;14(13):1247-54 [12952596.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] Nature. 1980 Dec 25;288(5792):724-7 [6256643.001]
  • [Cites] Carcinogenesis. 1985 Jun;6(6):883-6 [4006075.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:187-92 [3189008.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 25;17(16):6581-90 [2780288.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):323-31 [1686725.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79 [7673356.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):198-206 [15865885.001]
  • [Cites] Neurologist. 2005 Nov;11(6):362-5 [16286879.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):337-43 [16520474.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1025-34 [18667747.001]
  • [Cites] J Med Life. 2009 Oct-Dec;2(4):386-93 [20108752.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • (PMID = 20108752.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC3019011
  •  go-up   go-down


78. Ahmad FU, Gupta A, Sharma MC, Shukla G, Mehta VS: The enigmatic origin of subfrontal schwannomas: report of a case without hyposmia. Acta Neurochir (Wien); 2006 Jun;148(6):671-2; discussion 672
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 23-year-old male who presented with recurrent focal motor seizures, but had no hyposmia.
  • The tumor was completely removed by a subfrontal approach.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / etiology. Cranial Fossa, Anterior / pathology. Frontal Lobe / pathology. Neurilemmoma / diagnosis. Neurilemmoma / etiology. Schwann Cells / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Dura Mater / pathology. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Olfaction Disorders / etiology. Olfaction Disorders / physiopathology. Olfactory Nerve / pathology. Olfactory Nerve / physiopathology. S100 Proteins / metabolism. Seizures / etiology. Seizures / physiopathology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467962.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


79. Boiardi A, Bartolomei M, Silvani A, Eoli M, Salmaggi A, Lamperti E, Milanesi I, Botturi A, Rocca P, Bodei L, Broggi G, Paganelli G: Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol; 2005 Apr;72(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
  • Twenty-six recurrent Glioblastoma (rGBM) patients sequentially treated at the National Neurological Institute 'C Besta' were enrolled for a second surgery in order to remove recurrent tumor and to place an Ommaya reservoire to allow local delivery of chemotherapy and local pre-targeted radio-immunotherapy (RIT).
  • All patients had partial tumor resection and 75% of them had a residual tumor mass after exeresis larger than 2 cm.
  • We stress the concept that the combined treatments could be more effective if delivered into a smaller residual tumor mass and probably in an adjuvant setting, before tumour recurrence.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Mitoxantrone / administration & dosage. Radioimmunotherapy / methods. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Bone Marrow Diseases / chemically induced. Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Disease-Free Survival. Drug Delivery Systems / methods. Humans. Infusions, Intralesional. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Pilot Projects

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurooncol. 1988;6(1):75-83 [3397768.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurooncol. 1997 May;32(3):203-8 [9049881.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):207-12 [11870507.001]
  • [Cites] Invest New Drugs. 1985;3(2):85-93 [2410393.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):1-17 [3275753.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5952s-5956s [7493376.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Jun;16(3):227-35 [11471487.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):57-74 [2022973.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):631-8 [10210222.001]
  • [Cites] Eur J Cancer. 1978 Aug;14(8):851-6 [357162.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):157-62 [8699238.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):601-9 [10853818.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Strahlenther Onkol. 1992 Jun;168(6):361-8 [1621215.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] Orv Hetil. 2002 May 26;143(21):1201-4 [12073541.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):383-9 [9054951.001]
  • [Cites] J Neurooncol. 1992 Sep;14 (1):19-35 [1335043.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1289-94 [11106118.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1255-61 [3768871.001]
  • [Cites] J Neurosurg. 2003 Apr;98(4):935-6; author reply 936 [12691429.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(10):585-92 [7929529.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):39-47 [11763421.001]
  • [Cites] Cancer. 1994 Feb 1;73(3 Suppl):1076-82 [8306250.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):151-7 [10222435.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):255-7 [11300334.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 15925992.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


80. Seo YS, Chung TW, Kim IY, Bom HS, Min JJ: Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET. Clin Nucl Med; 2008 Jan;33(1):32-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET.
  • A 43-year-old man with a history of lung cancer, brain metastasis, and gamma knife radiosurgery underwent FDG PET/CT to differentiate recurrence from radiation necrosis.
  • Basal PET/CT scan showed equivocal uptake in the margin of necrotic tumor.
  • Proton magnetic resonance spectroscopy (1H-MRS) showed increased Cho/Cr ratio (1.7), which was consistent with tumor recurrence.
  • The patient underwent whole brain radiotherapy thereafter.
  • It is implicated that hyperglycemia-induced reduction of glucose uptake in recurrent brain tumors was less than in a normal brain, resulting in higher tumor-to-gray matter ratio.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Gadolinium DTPA. Glucose. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097254.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


81. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol; 2009 Mar 10;27(8):1268-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
  • These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
  • Tumor specimens obtained at first surgery were investigated for EGFR expression; EGFRvIII mutants; EGFR amplification; EGFR mutations in exons 18, 19, and 21; and pAkt.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. PTEN Phosphohydrolase / analysis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Anticancer Drugs. 2008 Feb;19(2):209-16 [18176118.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] Clin Lung Cancer. 2006 Dec;8 Suppl 1:S7-14 [17239291.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Science. 2007 Oct 12;318(5848):287-90 [17872411.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):159-63 [11302336.001]
  • (PMID = 19204207.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / epidermal growth factor receptor VIII; 7GR28W0FJI / Dacarbazine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; U68WG3173Y / Carmustine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2667826
  •  go-up   go-down


82. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):156-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
  • Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of concurrent bevacizumab with brain irradiation has not been extensively studied.
  • METHODS AND MATERIALS: After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression.
  • Three patients discontinued treatment because of Grade 3 central nervous system intratumoral hemorrhage, wound dehiscence, and bowel perforation.
  • Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma. Brain Neoplasms. Neoplasm Recurrence, Local. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy / adverse effects. Disease-Free Survival. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):646-8 [15577450.001]
  • [Cites] BMC Cancer. 2005;5:55 [15924621.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Neurosignals. 2005;14(5):207-21 [16301836.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):97-103 [16213059.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Acta Oncol. 2006;45(7):848-55 [16982549.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):723-7 [3940638.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):185-90 [17257702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90 [18234445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8 [17293237.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83 [9069310.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • (PMID = 19167838.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00595322
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS460357; NLM/ PMC3659401
  •  go-up   go-down


83. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys; 2005 Sep 1;63(1):47-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To systematically review the evidence for the use of stereotactic radiosurgery or stereotactic fractionated radiation therapy in adult patients with malignant glioma.
  • Outcomes considered were overall survival, quality of life or symptom control, brain tumor control or response and toxicity.
  • Radiosurgery used as salvage for recurrent or progressive malignant glioma after conventional external beam radiotherapy failure was reported in zero randomized trials, three prospective cohort studies, and five retrospective series.
  • There were only three prospective series and two retrospective studies reported for patients with recurrent or progressive malignant glioma.
  • CONCLUSIONS: For patients with malignant glioma, there is Level I-III evidence that the use of radiosurgery boost followed by external beam radiotherapy and BCNU does not confer benefit in terms of overall survival, local brain control, or quality of life as compared with external beam radiotherapy and BCNU.
  • There is also insufficient evidence regarding the benefits/harms in the use of stereotactic fractionated radiation therapy for patients with newly diagnosed or progressive/recurrent malignant glioma.
  • [MeSH-major] Brain Neoplasms / surgery. Evidence-Based Medicine. Glioma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Carmustine / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Humans. Neoplasm Recurrence, Local / surgery. Radiation Oncology. Salvage Therapy. Treatment Failure. United States

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111571.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  • [Number-of-references] 42
  •  go-up   go-down


84. Stüer C, Vilz B, Majores M, Becker A, Schramm J, Simon M: Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer; 2007 Dec 15;110(12):2799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1995 and 2005, 44 patients (26 women and 18 men) underwent surgery for a primary or recurrent piloA at the authors' institution.
  • RESULTS: There were 20 patients (45%) with supratentorial lobar piloA (including 10 temporal/temporomesial tumors, 5 parietal tumors, 3 insular tumors, 1 frontal tumor, and 1 occipital tumors), 12 patients with cerebellar piloA, 7 patients with brainstem piloA, 2 patients with opticochiasmatic PiloA, 1 patient with intramedullary piloA, and 2 patients with piloA of the basal ganglia.
  • All but 1 patient with a lobar tumor presented with epilepsy.
  • Tumor recurrence or disease progression was observed in 13 of 44 patients (30%).
  • CONCLUSIONS: PiloA in adult patients, surprisingly, often was not a benign disease.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Treatment Outcome